Is there a role for minimally invasive surgery in patients undergoing an interval cytoreductive surgery?

Yes! There is data supporting the feasibility. In the MISSION trial 82 women showed a complete clinical response to neoadjuvant chemotherapy (NACT). Of that, 30 were excluded for BMI >40 and/or ASA category III/IV. Of the 52 patients enrolled, 22 were undergoing laparotomy approach to interval debulking surgery (IDS) and 30 undergoing laparoscopic IDS. They found a feasibility rate of 36.5% (30 of 82 women with clinically complete response), which is the result of very strict inclusion criteria ...